|
2016 Journal Article Pulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarinMargolis, Jay M., Deitelzweig, Steven, Kline, Jeffrey, Tran, Oth, Smith, David M., Crivera, Concetta, Bookhart, Brahim and Schein, Jeff (2016). Pulmonary embolism inpatients treated with rivaroxaban had shorter hospital stays and lower costs compared with warfarin. Clinical Therapeutics, 38 (11), 2496-2503. doi: 10.1016/j.clinthera.2016.09.007 |
|
2016 Journal Article Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissionsMargolis, Jay M., Deitelzweig, Steven, Kline, Jeffrey, Tran, Oth, Smith, David M., Bookhart, Brahim, Crivera, Concetta and Schein, Jeff (2016). Shorter hospital stays and lower costs for rivaroxaban compared with warfarin for venous thrombosis admissions. Journal of the American Heart Association, 5 (10) e003788. doi: 10.1161/JAHA.116.003788 |
|
2016 Journal Article Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient settingDeitelzweig, Steven, Laliberte, Francois, Crivera, Concetta, Germain, Guillaume, Bookhart, Brahim K., Olson, William H., Schein, Jeffrey and Lefebvre, Patrick (2016). Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting. Clinical Therapeutics, 38 (8), 1803-1816. doi: 10.1016/j.clinthera.2016.07.002 |
|
2016 Journal Article Multidrug-resistant gram-negative bacterial infections in the hospital setting: Overview, implications for clinical practice, and emerging treatment optionsCerceo, Elizabeth, Deitelzweig, Steven B., Sherman, Bradley M. and Amin, Alpesh N. (2016). Multidrug-resistant gram-negative bacterial infections in the hospital setting: Overview, implications for clinical practice, and emerging treatment options. Microbial Drug Resistance, 22 (5), 412-431. doi: 10.1089/mdr.2015.0220 |
|
2016 Journal Article Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillationDeitelzweig, Steve, Evans, Michael, Hillson, Eric, Trocio, Jeffrey, Bruno, Amanda, Tan, Wilson, Lingohr-Smith, Melissa, Singh, Prianka and Lin, Jay (2016). Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation. Current Medical Research and Opinion, 32 (1), 87-94. doi: 10.1185/03007995.2015.1103217 |
|
2016 Conference Publication Compare major bleeding risk and associated costs among Nvaf patients with Cha2Ds2-vasc score >= 3 newly anticoagulated with apixaban versus warfarinDeitelzweig, Steven, Gupta, Kiran, Ogbonnaya, Augustina, Shah, Manan, Farrelly, Eileen, Lokhandwala, Tasneem, Eaddy, Michael and Squibb, Bristol-Myers (2016). Compare major bleeding risk and associated costs among Nvaf patients with Cha2Ds2-vasc score >= 3 newly anticoagulated with apixaban versus warfarin. 65th Annual Scientific Session and Expo of the American College of Cardiology (ACC), Chicago, United States, April 02-04, 2016. San Diego, United States: Elsevier. doi: 10.1016/S0735-1097(16)30877-4 |
|
2016 Conference Publication Hospital readmissions among patients with nonvalvular atrial fibrillation treated with the new oral anticoagulants, apixaban, dabigatran, and rivaroxabanDeitelzweig, Steven, Gupta, Kiran, Nadkarni, Anagha, Trocio, Jeffrey, Lin, Jay and Lingohr-Smith, Melissa (2016). Hospital readmissions among patients with nonvalvular atrial fibrillation treated with the new oral anticoagulants, apixaban, dabigatran, and rivaroxaban. 65th Annual Scientific Session and Expo of the American College of Cardiology (ACC), Chicago, United States, April 02-04, 2016. San Diego, United States: Elsevier. doi: 10.1016/S0735-1097(16)30806-3 |
|
2016 Conference Publication Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitorsDeitelzweig, S., Neuman, R., Lingohr-Smith, M. and Lin, J. (2016). Hospital resource utilization, cost and inpatient mortality associated with hospitalizations for major bleeding among atrial fibrillation patients treated with factor Xa inhibitors. Congress of the European-Society-of-Cardiology (ESC), Rome Italy, Aug 27-31, 2016. OXFORD: OXFORD UNIV PRESS. |
|
2016 Conference Publication Hospital Length Of Stay And Hospitalization Costs For Pulmonary Embolism Comparing Patients Receiving Rivaroxaban Or WarfarinKline, J. A., Deitelzweig, S., Margolis, J. M., Raut, M., Tran, O., Smith, D. M., Crivera, C., Bookhart, B., Schein, J. and Olson, W. (2016). Hospital Length Of Stay And Hospitalization Costs For Pulmonary Embolism Comparing Patients Receiving Rivaroxaban Or Warfarin. International Conference of the American-Thoracic-Society (ATS), San Francisco, United States, May 13-18, 2016. NEW YORK: AMER THORACIC SOC. |
|
2016 Conference Publication An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulantsDeitelzweig, Steve, Bruno, Amanda, Trocio, Jeffrey, Tate, Natalie, Gupta, Kiran, Lin, Jay and Lingohr-Smith, Melissa (2016). An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Abingdon, Oxfordshire, United Kingdom: Taylor & Francis. doi: 10.1185/03007995.2015.1131676 |
|
2016 Conference Publication Comparison of rivaroxaban or warfarin use for venous thromboembolism on inpatient length of stayDeitelzweig, Steven, Kline, Jeffrey, Margolis, Jay M., Raut, Monika, Tran, Oth, Smith, David, Crivera, Concetta, Bookhart, Brahim, Schein, Jeff and Olson, William (2016). Comparison of rivaroxaban or warfarin use for venous thromboembolism on inpatient length of stay. 65th Annual Scientific Session and Expo of the American College of Cardiology (ACC), Chicago, United States, April 02-04, 2016. San Diego, United States: Elsevier. doi: 10.1016/S0735-1097(16)32066-6 |
|
2016 Conference Publication Health Care Costs Among Patients Diagnosed with Deep Vein Thrombosis in the Outpatient Setting and Treated with Rivaroxaban Versus Low-Molecular-Weight Heparin and WarfarinDeitelzweig, S., Laliberte, F., Raut, R., Germain, G., Bookhart, B. K., Olson, W. H., Schein, J. and Lefebvre, P. (2016). Health Care Costs Among Patients Diagnosed with Deep Vein Thrombosis in the Outpatient Setting and Treated with Rivaroxaban Versus Low-Molecular-Weight Heparin and Warfarin. ISPOR 21st Annual International Meeting, Washington, DC United States, 21 – 25 May 2016. New York, NY United States: Elsevier. doi: 10.1016/j.jval.2016.03.102 |
|
2015 Journal Article Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measureMcHorney, Colleen A., Crivera, Concetta, Laliberte, Francois, Nelson, Winnie W., Germain, Guillaume, Bookhart, Brahim, Martin, Silas, Schein, Jeffrey, Lefebvre, Patrick and Deitelzweig, Steven (2015). Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Current Medical Research and Opinion, 31 (12), 2167-2173. doi: 10.1185/03007995.2015.1096242 |
|
2015 Journal Article A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: Balancing the risks and benefitsAmin, Alpesh and Deitelzweig, Steven (2015). A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: Balancing the risks and benefits. Thrombosis Journal, 13 (29) 29, 29. doi: 10.1186/s12959-015-0056-y |
|
2015 Journal Article Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trialAmin, Alpesh, Deitelzweig, Steve, Jing, Yonghua, Makenbaeva, Dinara, Wiederkehr, Daniel, Lin, Jay and Graham, John (2015). Comparison of medical costs of patients with atrial fibrillation unsuitable for warfarin treatment with apixaban or aspirin based on averroes trial. Clinical and Applied Thrombosis/Hemostasis, 21 (3), 235-240. doi: 10.1177/1076029613507335 |
|
2015 Conference Publication Comparison of Major Bleeding Risk and Associated Costs Among Newly Anticoagulated Non-valvular Atrial Fibrillation PatientsDeitelzweig, Steven, Bruno, Amanda, Tate, Natalie, Ogbonnaya, Augustina, Shah, Manan, Farrelly, Eileen, Lokhandwala, Tasneem, Gupta, Kiran and Eaddy, Michael (2015). Comparison of Major Bleeding Risk and Associated Costs Among Newly Anticoagulated Non-valvular Atrial Fibrillation Patients. Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association (AHA), Orlando, United States, Nov 07-11, 2015. LIPPINCOTT WILLIAMS & WILKINS. |
|
2015 Conference Publication Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation patients naive to oral anticoagulation and newly treated with novel oral anticoagulantsDeitelzweig, S., Bruno, A., Tate, N., Ogbonnaya, A., Shah, M., Farrelly, E., Lokhandwala, T., Gupta, K. and Eaddy, M. (2015). Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation patients naive to oral anticoagulation and newly treated with novel oral anticoagulants. Congress of the European-Society-of-Cardiology (ESC), London, England, United Kingdom, Aug 29-Sep 02, 2015. OXFORD: OXFORD UNIV PRESS. |
|
2015 Conference Publication Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients treated with the new oral anticoagulants using an electronic medical record database in the USDeitelzweig, S., Bruno, A., Trocio, J., Tate, N., Gupta, K., Lin, J. and Lingohr-Smith, M. (2015). Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients treated with the new oral anticoagulants using an electronic medical record database in the US. Congress of the European-Society-of-Cardiology (ESC), London, England, United Kingdom, Aug 29-Sep 02, 2015. OXFORD: OXFORD UNIV PRESS. |
|
2015 Conference Publication A Conservative Aproach to Assess Warfarin Time-in-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients in An Integrated Healthcare Delivery System Setting in the U.SDeitelzweig, S., Evans, M., Hillson, E., Trocio, J., Bruno, A., Tan, W., Lingohr-Smith, M. and Lin, J. (2015). A Conservative Aproach to Assess Warfarin Time-in-Therapeutic Ranges Among Nonvalvular Atrial Fibrillation Patients in An Integrated Healthcare Delivery System Setting in the U.S. ISPOR 20th Annual International Meeting, Philadelphia, PA United States, 16-20 May 2015. New York, NY United States: Elsevier. doi: 10.1016/j.jval.2015.03.848 |
|
2014 Conference Publication Evaluation of Differences in Medical Costs Associated with Venous Thromboembolism Prophylaxis with Desirudin Vs. Low Molecular Weight Heparin Among Patients Undergoing Total Hip Replacement SurgeryDeitelzweig, Steven, Nutescu, Edith A., Meyer, James, Lin, Jay, Lingohr-Smith, Melissa and Amin, Alpesh N. (2014). Evaluation of Differences in Medical Costs Associated with Venous Thromboembolism Prophylaxis with Desirudin Vs. Low Molecular Weight Heparin Among Patients Undergoing Total Hip Replacement Surgery. 56th Annual Meeting of the American-Society-of-Hematology, San Francisco Ca, Dec 06-09, 2014. WASHINGTON: AMER SOC HEMATOLOGY. |
